{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:04:39Z","timestamp":1793444679264,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,14]],"date-time":"2027-05-14T00:00:00Z","timestamp":1810252800000},"content-version":"am","delay-in-days":590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:41:49Z","timestamp":1772178109000},"page":"360-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma\u2014Where we are and where we\u2019re headed"],"prefix":"10.1053","volume":"62","author":[{"given":"Rahul","family":"Lakhotia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.003_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.003_bib0002","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2025746","article-title":"Burkitt's lymphoma","volume":"387","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood.2024026019","article-title":"Frontline treatment of follicular lymphoma: what will it take to change current practice?","volume":"146","author":"Bachy","year":"2025","journal-title":"Blood"},{"issue":"27","key":"10.1053\/j.seminhematol.2026.02.003_bib0004","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1053\/j.seminhematol.2026.02.003_bib0005","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.003_bib0007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0008","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA","volume":"5","author":"Kostakoglu","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00277-010-1135-6","article-title":"Limited role of interim PET\/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"90","author":"Yoo","year":"2011","journal-title":"Ann Hematol"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.02.003_bib0010","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0011","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1053\/j.seminhematol.2026.02.003_bib0012","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1053\/j.seminhematol.2026.02.003_bib0013","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.003_bib0014","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.17251","article-title":"Circulating tumour DNA in B-cell lymphomas: current state and future prospects","volume":"193","author":"Lakhotia","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0016","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.02.003_bib0017","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1182\/bloodadvances.2025016332","article-title":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL","volume":"9","author":"Arnason","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.003_bib0018","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0019","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.02.003_bib0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with Obinutuzumab or Rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.02.003_bib0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of Obinutuzumab- or Rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients","volume":"132","author":"Pott","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0022","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.02.003_bib0023","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.003_bib0024","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"364","key":"10.1053\/j.seminhematol.2026.02.003_bib0026","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0027","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.003_bib0028","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1182\/blood-2023-190570","article-title":"Impact of sequence uniqueness on MRD monitoring in NGS immunoglobulin sequencing: an analysis of Ig loci among >1200 diffuse large B-cell lymphoma patients tested by Clonoseq","volume":"142","author":"Simmons","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.003_bib0029","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.02.003_bib0030","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2021-151096","article-title":"A prospective study of clonal evolution in follicular lymphoma: circulating tumor DNA correlates with overall tumor burden and fluctuates over time without therapy","volume":"138","author":"Distler","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0032","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0033","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0034","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2026.02.003_bib0035","article-title":"Risk assessment with ultra-low-pass whole-genome sequencing of cell-free DNA for large B-cell lymphoma","volume":"9","author":"Zhao","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0036","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","article-title":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"140","author":"Cherng","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0037","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.003_bib0038","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.003_bib0039","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0040","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1053\/j.seminhematol.2026.02.003_bib0041","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0042","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0043","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.02.003_bib0044","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 3.2026. Published March 12, 2026. Accessed March 16, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO-25-01587","article-title":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study","volume":"44","author":"Krupka","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2026.02.003_bib0046","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2025.43.16_suppl.7000","article-title":"Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.02.003_bib0047","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.003_bib0048","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.003_bib0049","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2026.02.003_bib0050","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2019-122450","article-title":"Response-adapted therapy in HIV-associated diffuse large B-cell lymphoma: updated results of a prospective phase II study of short-course-EPOCH-RR","volume":"134","author":"Gastwirt","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.02.003_bib0051","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.02.003_bib0052","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.02.003_bib0053","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol"},{"issue":"S3","key":"10.1053\/j.seminhematol.2026.02.003_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70110_LBA1","article-title":"LBA1 | the benefit of pola-R-CHP in DLBclass-defined molecular subsets of newly diagnosed dlbcl in the polarix trial","volume":"43","author":"Calabretta","year":"2025","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0056","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.02.003_bib0057","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10441","key":"10.1053\/j.seminhematol.2026.02.003_bib0058","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"10044","key":"10.1053\/j.seminhematol.2026.02.003_bib0059","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.003_bib0060","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"10.1053\/j.seminhematol.2026.02.003_bib0061","doi-asserted-by":"crossref","first-page":"LBA-6-LBA","DOI":"10.1182\/blood-2024-212973","volume":"144","author":"Fenske","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.003_bib0062","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.003_bib0063","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.02.003_bib0064","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.003_bib0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9759","key":"10.1053\/j.seminhematol.2026.02.003_bib0066","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.02.003_bib0067","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0068","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.02.003_bib0069","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood.2020008119","article-title":"Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma","volume":"137","author":"Bolen","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.003_bib0070","doi-asserted-by":"crossref","first-page":"e3205","DOI":"10.1002\/hon.3205","article-title":"Personalised therapy in follicular lymphoma \u2013 is the dial turning?","volume":"42","author":"Linton","year":"2024","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.003_bib0071","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.003_bib0072","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.02.003_bib0073","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0074","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.003_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The development of liquid biopsy for research and clinical practice in lymphomas: report of the 15-ICML workshop on ctDNA","volume":"38","author":"Rossi","year":"2020","journal-title":"Hematol Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:11Z","timestamp":1778728031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000120"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma\u2014Where we are and where we\u2019re headed","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}